Cancer Incidence Predictions (Finnish Experience)

Similar documents
Trends in Irish cancer incidence with predictions to 2020

Predictions of cancer incidence in Poland in 2019

National Cancer Statistics in Korea, 2014

Information Services Division NHS National Services Scotland

Cancer incidence in the United Kingdom: projections to the year 2030

Information Services Division NHS National Services Scotland

Cancer Projections. Incidence to

MEASURING CANCER CURE IN IRELAND

Cancer survival in Hong Kong SAR, China,

Cancer projections National Cancer Registry

Cancer survival in Shanghai, China,

CHAPTER 10 CANCER REPORT. Germaine Wong Kirsten Howard Jonathan Craig Stephen McDonald Jeremy Chapman

Cancer survival in Seoul, Republic of Korea,

APPENDIX ONE: ICD CODES

Republican Research and Practical Center for Radiation Medicine and Human Ecology. Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus

F i t p o w e r 5 a n d p o i s s o n A g e- Period-Cohort models for prediction of cancer incidence

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Nation nal Cancer Institute. Prevalence Projections: The US Experience

Measuring and predicting cancer incidence, prevalence and survival in Finland

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY

Cancer incidence in type 1 diabetes: A 5-country study of 9,000 cancers in type 1 diabetic individuals. Electronic Supplementary Material

CHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster

Cancer in Central and South America BOLIVIA

Overview of 2009 Hong Kong Cancer Statistics

Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium

Some experiences from regional geospatial mapping of cancer cases and incidences Predictions

Information Services Division NHS National Services Scotland

Cancer Prediction Accounting for Geographic Disparity in Incidence and Survival

Epidemiology in Texas 2006 Annual Report. Cancer

Assessment of lead-time bias in estimates of relative survival for breast cancer

AN EMPIRICAL EVALUATION OF PERIOD SURVIVAL ANALYSIS USING DATA FROM THE CANADIAN CANCER REGISTRY. Larry F. Ellison MSc, Statistics Canada

Overview of 2010 Hong Kong Cancer Statistics

Cancer in the Northern Territory :

Supplementary Online Content

Cancer in Estonia 2014

M. J. Rutherford 1,*, T. M-L. Andersson 2, H. Møller 3, P.C. Lambert 1,2.

CANCER FACTS & FIGURES For African Americans

Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision

Overview of 2013 Hong Kong Cancer Statistics

Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry

Lecture Outline Biost 517 Applied Biostatistics I

Modelled prevalence. Marc COLONNA. January 22-23, 2014 Ispra

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Spatiotemporal models for disease incidence data: a case study

Estimating and modelling relative survival

Cancer in Utah: An Overview of Cancer Incidence and Mortality from

Cancer survival in Busan, Republic of Korea,

Cancer in New Mexico 2017

Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption

Cancer in New Mexico 2014

Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts

Research Article Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program

Smoking and Mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC)

Cancer Survival in Wales, Goroesi Cancr yng Nghymru,

Cancer survival, incidence and mortality by Area Health Service in NSW 1994 to 2000

Diagnosing cancer in an emergency: Patterns of emergency presentation of cancer in Ireland

Trends in Cancer Survival in NSW 1980 to 1996

Prediction of Cancer Incidence and Mortality in Korea, 2013

Cancer in Ireland : Annual Report of the National Cancer Registry

Special issue: NORDCAN Cancer data from the Nordic countries

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation

Cancer in Ireland with estimates for

Overview of Hong Kong Cancer Statistics of 2015

Prediction of Cancer Incidence and Mortality in Korea, 2018

Up-to-date survival estimates from prognostic models using temporal recalibration

*

Macmillan-NICR Partnership: GP Federation Cancer Profiles (with Prevalence )

Epidemiology of weak associations The case of nutrition and cancer. Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY

Hazelinks - Cancer incidence analysis (First data extraction)

Trends in Cancer Survival in Scotland

ST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods

Cancer prevalence. Chapter 7

Time Trends of Italian Former Smokers and Projections Using a Bayesian Age Period Cohort Model

BEIR VII: Epidemiology and Models for Estimating Cancer Risk

NICaN workshop: Colorectal Cancer Follow-up

Cancer survival by stage at diagnosis in Wales,

Cancer Incidence and Mortality in Los Alamos County and New Mexico By Catherine M. Richards, M.S. 8

BOUNDARY COUNTY CANCER PROFILE

Cancer Dispari,es in Indiana

ALL CANCER (EXCLUDING NMSC)

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment

Physician On-line Staging Application. Darlene Dale Head, PMH Cancer Registry

Cancer in Ireland : Annual Report of the National Cancer Registry

Sample Size Considerations. Todd Alonzo, PhD

Cancer occurrence in Danish diabetes patients: Duration and insulin effects

Cancer Statistics in Korea: Incidence, Mortality and Survival in

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

IJC International Journal of Cancer

Cancer survival in Bhopal, India,

Health Resource Review - Section 2.4

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

ALL CANCER (EXCLUDING NMSC)

Cancer Incidences in Rural Delhi

Biost 590: Statistical Consulting

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Methodology for the Survival Estimates

Transcription:

Cancer Incidence Predictions (Finnish Experience) Tadeusz Dyba Joint Research Center EPAAC Workshop, January 22-23 2014, Ispra

Rational for making cancer incidence predictions Administrative: to plan the allocation of the resources (then predictions should be as accurate as possible) Scientific: to evaluate the success of disease control (then predictions that do not come true are useful)

Example of administrative prediction: Updating cancer registry data (Annual Report of Finnish Cancer Registry 2006/2007)

Example of scientific prediction:

Precision of prediction "Predictions are often given as point forecasts with no guidance as to their likely accuracy." "Given their importance, it is perhaps surprising and rather regrettable, that many [ ] do not regularly produce prediction intervals, and that most predictions are still given as a single value." Chris Chatfield, Time-Series Forecasting, Chapman&Chall, 2001.

Why use predictions intervals in incidence predictions? Monitoring a range of possible future outcomes Evaluation of cancer prevention actions Some predictions more accurate than others Elimination of absolutely inaccurate predictions

Calculating prediction intervals Using the formula for calculating the variance of conditional distribution var(c it ) = var( E(c it θ it ) ) + E(var(c it θ it ) ) can be shown for any model: var(c T ) = var(θ T ) + E(θ T ) where θ it is the estimator of predicted number of cases c it uncertainty about = uncertainty about + uncertainty about the predicted the parameters of the future number of cases model distribution ------------------------ Confidence Interval ----------------------------------------------------- Prediction Interval

Why use simple models for cancer incidence prediction? Rule of parsimony ("status quo" assumption lying behind any prediction) Complicated models are not likely to hold in the future Lack of information or of reliable information about causes of cancers Short prediction interval; more precise prediction (if model holds) Clear interpretation

AGE PERIOD MODELS Decreasing trends of cancer incidence lne(i it ) = α i + βt β i Increasing trends of cancer incidence I it = c it / n it c it = number of cases n it = number of person-years i = age, t = period E( I it ) = α i + β i t E( I it ) = α i ( 1+ βt ) no non-identifiability property Assumption about: c it Poisson I it, age-adjusted Normal

Empirical coverage error of ex post predictions Finnish data (1953-2003) Site Females Males Lip 95 95 Oesophagus 95 95 Stomach 84 100 Colon 97 73 Rectum 89 97 Liver 78 65 Gallbladder 76 65 Pancreas 89 97 Lung 84 31 Corpus uteri 86 --- Ovary 86 --- Kidney 84 78 Bladder 76 70 Skin melanoma 89 86 Skin non-melanoma 68 81 Nervous system 76 78 Thyroid 68 86 Non-Hodgkin 85 86 Leukaemia 81 92 cancer sites without screening activities, horizon of prediction = 5 years, 32 ex post predictions per site

Site specific predictions - Lung Cancer Hakulinen T and Pukkala E, Int J Epidemiol, 1981 a simulation model to predict lung cancer incidence in Finland based on historical smoking habits and possible future scenarios of starting and quiting smoking - Breast Cancer Seppanen et al., Cancer Cause Control, 2006 predicting breast cancer incidence under historical and possible future scenarios of screening practices in Finland

Examples of predictive models for Finland based on age-period-region specific data - cancer control is by region in Finland - stratification by region increases homogenity of data eliminating extra-poisson variation for the more common cancers No. Model D.F. Pearson s X 2 Deviance Dev. + 2*NP 1 α i 702 991.2 1044.6 1070.6 2 α i ( 1 + βt ) 701 983.2 1037.8 1065.8 3 α i ( 1 + γ r + βt ) 697 701.6 724.6 760.6 4 α i ( 1 + γ r + β r t ) 693 695.9 718.9 762.9 5 α i + β i t 689 966.6 1024.5 1076.5 6 α i r 650 644.7 677.9 807.9 7 α i r ( 1 + βt ) 649 637.0 671.1 803.1 8 α i r ( 1 + β r t ) 645 634.2 667.0 807.0 9 α i r + β i t 638 619.8 657.4 811.4 10 α i r + β i r t 588 577.6 609.9 863.9 The models for cancer incidence specific to age(α i ), period(β) and to region(γ r ) applied for cancer sites with increasing (or stable) incidence pattern. The example of fit is for lung cancer in females in Finland

Predictions for males in Finland as age-adjusted incidence rates based on age-period-region models

Other approaches to prediction Age-period-cohort models Moller B, et al. Stat in Med, 2003 (empirical evaluation of using Age-Period-Cohort models for prediction, applying different methods using data from Nordic countries, no evaluation of the precision of the performed predictions by means of prediction interval) Rutherford M et al. Int J Biost 2012, Phd Thesis 2011 (in the framework of flexible parametric modelling forces period and cohort cubic spline functions to be linear beyond the boundary knot in order to predict the future incidence) Bayesian age-period-cohort models Bashir G and Esteve J, J of Epidemiol and Biostat, 2001 Bray I, Appl Stat, 2002 Baker A and Bray I, Am. J Epidemiol, 2005 Cleries R et al., Stat Med, 2012 (choice of smoothing priors is crucial, long credible intervals) Generalized additive models Clements et al., Biostatistics, 2005 (prediction interval more precise than those from Bayesian approach)

Software for incidence prediction - Published papers are sometimes accompanied by computer code to perform prediction or the code is available upon request, many Bayesian predictions use Winbugs software - Nordpred package developed in Norway, written in R software http://www.kreftregisteret.no/en/research/projects/nordpred/nordpred-software/ Moller B, et al. Stat in Med, 2003 Engholm et al., Association of Nordic Cancer Registries. Danish Cancer Society, 2009 - A four presented here age-period models can be applied using Stata macros http://www.cancer.fi/syoparekisteri/en/general/links/, Hakulienen T and Dyba, Stat Med, 1994; Dyba T and Hakulinen T, Stat Med, 1997; 2000 - Prediction based on APC models using restricted cubic splines uses Stata macros Rutherford M et al., Int J Biost 2012; Stata Jour 2012; Rutherford M, Phd Thesis 2011 - On line analysis, allowing to perform predictions for certain data sets Nordic countries: http://www.kreftregisteret.no/en/research/projects/nordpred/nordpred-software/ Other countries: http://www-dep.iarc.fr/whodb/predictions_sel.htm

Closing remarks Predictive methods should clearly state assumptions used during prediction process One method of fitting all cancer sites doesn't exist Performed cancer incidence predictions often lack necessary measure of precision Mathematically advanced predictive methods/models are hard to interpret The need of collecting software used by different prediction methods at one place (website?) Without external information on cancer etiology, latency time, screening activities performing cancer incidence predictions will remain a challenge

THANK YOU

Long-term Bayesian predictions for Finland: numbers of new cases in females 1990-1994 Site Observed Projected 90% CI Oesophagus 442 440 130; 1552 Lung 2208 2152 706; 6539 Melanoma 1240 1675 431; 6216 Breast 13930 15032 4952; 46354 Brain 1948 2117 643; 8285 Bashir G and Esteve J, J of Epidemiol and Biostat, 2001

Posterior estimates of the precision parameters of the predictive model Timescale Posterior median 90% Credible Interval Age 18.6 6.9; 52.5 Period 674.2 54.9; 2993.4 Cohort 513.2 61.6; 2724.3 Bray I, Appl Stat, 2002

Moller B, et al. Stat in Med, 2003

Moller B, et al. Stat in Med, 2003

Moller B, et al. Stat in Med, 2003

Moller B, et al. Stat in Med, 2003